Group 1: Company Overview - The company's order structure aligns with the revenue distribution across its business segments, with intelligent manufacturing accounting for approximately 45% and digital conferencing orders for about 30% [2]. Group 2: Product Development - The intelligent anesthesia robot has successfully completed over ten clinical trials with positive feedback, aiming to obtain the Class III medical device registration by the end of 2028 [3]. - The company plans to leverage core products like the intelligent anesthesia robot and tumor adaptive radiotherapy platform to create comprehensive smart hospital solutions for market promotion [3]. Group 3: Financial Performance - The company has experienced slow revenue growth and declining net profits over the past two years due to three main factors: increased market competition leading to low-price bidding, significant investment in technology innovation and new product development, and delays in project bidding schedules from downstream clients [3]. - In 2025, the company intensified market expansion efforts, achieving a record high in new contracts signed in the first half of the year, with a growth rate of 282.6% [3].

Group 1 - The company has successfully completed over ten clinical trials for its intelligent anesthesia robot and aims to shorten the process through a "multi-center" layout, targeting certification for Class III medical devices by the end of 2028 [1] - The company plans to develop a comprehensive smart hospital solution centered around products such as the intelligent anesthesia robot and tumor adaptive radiotherapy platform for sales [1]